INNOPRAN XL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Innopran Xl, and what generic alternatives are available?
Innopran Xl is a drug marketed by Ani Pharms and is included in one NDA.
The generic ingredient in INNOPRAN XL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Innopran Xl
A generic version of INNOPRAN XL was approved as propranolol hydrochloride by INNOGENIX on October 22nd, 1985.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for INNOPRAN XL?
- What are the global sales for INNOPRAN XL?
- What is Average Wholesale Price for INNOPRAN XL?
Summary for INNOPRAN XL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 130 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,888 |
| Drug Prices: | Drug price information for INNOPRAN XL |
| What excipients (inactive ingredients) are in INNOPRAN XL? | INNOPRAN XL excipients list |
| DailyMed Link: | INNOPRAN XL at DailyMed |
Recent Clinical Trials for INNOPRAN XL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| United States Department of Defense | Early Phase 1 |
| University of Missouri-Columbia | Early Phase 1 |
| University of North Carolina, Chapel Hill | Phase 2 |
Pharmacology for INNOPRAN XL
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for INNOPRAN XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | INNOPRAN XL | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021438-001 | Mar 12, 2003 | BX | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Ani Pharms | INNOPRAN XL | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021438-002 | Mar 12, 2003 | BX | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INNOPRAN XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ani Pharms | INNOPRAN XL | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021438-001 | Mar 12, 2003 | ⤷ Start Trial | ⤷ Start Trial |
| Ani Pharms | INNOPRAN XL | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021438-002 | Mar 12, 2003 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INNOPRAN XL
See the table below for patents covering INNOPRAN XL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 4369752 | ⤷ Start Trial | |
| European Patent Office | 1432411 | FORMES POSOLIGIQUES MULTIPARTICULAIRES A LIBERATION PROGRAMMEE ET PROLONGEE DE PROPANOLOL (TIMED, SUSTAINED RELEASE MULTI-PARTICULATE DOSAGE FORMS OF PROPRANOLOL) | ⤷ Start Trial |
| South Korea | 20040084890 | ⤷ Start Trial | |
| Norway | 335070 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch